Careers

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • HSCA Connect
  • Events
    • 2025 HSCA National Pharmacy Forum
    • Past Events
  • Issues
  • Resources
    • Congressional Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • HSCA Connect
  • Events
    • 2025 HSCA National Pharmacy Forum
    • Past Events
  • Issues
  • Resources
    • Congressional Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News

HSCA Submits Comments to FDA on Using Unique Device Identifiers in Medical Device Safety Communications to Support Accuracy, Quality, and Patient Safety

January 18, 2021 by Brigid Hasson 2019 Press Releases 0 comments

Washington, DC (January 19, 2021) – The Healthcare Supply Chain Association (HSCA) Committee for Healthcare eStandards (CHeS) today submitted comments to the U.S. Food and Drug Administration (FDA) encouraging the agency to use unique device identifiers (UDI) to improve FDA communications regarding the safety of medical devices.

Patients across the country rely on medical devices in their day-to-day lives, and timely, informative communications in the event of medical device issues are critical to patient care. The FDA solicited feedback from healthcare stakeholders on ways to strengthen the agency’s medical device safety communications to help support patient safety.

“The ability to track and recall medical devices when issues arise is critical to protecting patients, many of whom depend on medical devices,” said Curt Miller, Executive Director of CHeS. “Incorporating UDIs into all FDA data sets, submissions, and communications will enable healthcare stakeholders to quickly identify and withdraw relevant products and improve overall accurate identification and traceability while promoting patient safety.”

Click here to read the full release.

Click here to read the full comments.

Prev
Next

Related Posts

Comments of the Healthcare Supply Chain Association to FDA on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
January 11, 2019

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Announces 2019 Board of Directors and Names GNYHA Ventures President Lee Perlman Board Chair
January 24, 2019

Washington, DC (January, 2019) – The Healthcare Supply Chain Association (HSCA)...

Learn more
HSCA Names Leading National Healthcare Expert Khatereh Calleja as President & CEO
April 2, 2019

Washington, DC (April 2, 2019) – The Healthcare Supply Chain Association (HSCA)...

Learn more
HSCA E&C Letter on Improving Competition in the Generic Marketplace
April 1, 2019

Dear Chairman Pallone and Ranking Member Walden, I am writing to you on behalf...

Learn more

Our Office

Healthcare Supply Chain Association
750 9th Street NW, Suite 650
Washington, DC 20001

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Response to the U.S. Department of Commerce’s Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
    May 8, 2025
  • HSCA Response to the U.S. Trade Representative’s Request for Comments on Unfair and Non-Reciprocal Foreign Trade Practices
    March 12, 2025